These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26801207)

  • 1. Regorafenib-induced hand-foot skin reaction with striking epidermal dysmaturation - a new histopathological pattern associated with the use of multi-kinase inhibitors.
    Llamas-Velasco M; Hegyi I; Hesterberg U; Daudén E; Requena L; Kempf W
    Br J Dermatol; 2016 Jul; 175(1):216-7. PubMed ID: 26801207
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome].
    Delgado-Téllez L; Campos Fernández de Sevilla MA; Tutau F
    Farm Hosp; 2009; 33(5):288-9. PubMed ID: 19775581
    [No Abstract]   [Full Text] [Related]  

  • 3. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hand-foot syndrome and sorafenib].
    Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial granulomatous drug reaction to sorafenib.
    Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
    Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
    Jain L; Gardner ER; Figg WD; Chernick MS; Kong HH
    Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D; Kocák I
    Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen.
    García-Gutiérrez I; Acevedo M; Tornero P; Matilla A; Márquez L; Sánchez-Herrero A; Prieto-García A
    J Investig Allergol Clin Immunol; 2019 Aug; 29(4):300-302. PubMed ID: 31478526
    [No Abstract]   [Full Text] [Related]  

  • 11. Reader seeks clarification on hand-foot skin reaction.
    Clark M
    Clin J Oncol Nurs; 2008 Jun; 12(3):395; author reply 395. PubMed ID: 18564457
    [No Abstract]   [Full Text] [Related]  

  • 12. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.
    Sato J; Ishikawa H; Hamauchi S; Yamawaki Y; Mori K; Kiyohara Y; Yoshikawa S; Yamazaki K; Yasui H; Shino M
    J Oncol Pharm Pract; 2020 Mar; 26(2):361-367. PubMed ID: 31106665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythema multiforme-like drug reaction to sorafenib.
    Lewin J; Farley-Loftus R; Pomeranz MK
    J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 16. Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
    Guerra JR; Suelves AM; Bella A; Lolo D
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24842353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Palmoplantar cutaneous reaction to sorafenib].
    Echeverría B; Llombart B; Botella-Estrada R; Guillén C
    Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
    [No Abstract]   [Full Text] [Related]  

  • 18. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
    Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
    [No Abstract]   [Full Text] [Related]  

  • 19. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
    McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
    Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.